Advanced in WT1-Related Wilms Tumor Syndromes

Dr. Julio J. Hajdenberg

Hematology Oncology | Hematology | Oncology
2 Independence Dr, 
Kennebunk, ME 
Clinical Trials:Currently Recruiting for 1 Trial
Advanced in WT1-Related Wilms Tumor Syndromes
2 Independence Dr, 
Kennebunk, ME 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Julio Hajdenberg is a Hematologist Oncology specialist and a Hematologist in Kennebunk, Maine. Dr. Hajdenberg is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Histiocytosis, Reticulohistiocytoma, Factor 5 Deficiency, Prostate Cancer, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 16 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in ME
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO

Locations

2 Independence Dr, Kennebunk, ME 04043

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Phase III Trial of Immunotherapy-Based Combination Therapy With or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial)
Phase III Trial of Immunotherapy-Based Combination Therapy With or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial)
Enrollment Status: Recruiting
Publish Date: September 09, 2025
Intervention Type: Drug, Procedure
Study Phase: Phase 3
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2025
Intervention Type: Drug, Biological, Procedure, Other, Radiation
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Filgrastim, Nivolumab, Pegfilgrastim, Vinblastine
Study Phase: Phase 3
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Prednisone, Rituximab, Vincristine Sulfate
Study Phase: Phase 2
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
A Randomized Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With High-Risk Castrate Biochemically Relapsed Prostate Cancer After Local Therapy
A Randomized Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With High-Risk Castrate Biochemically Relapsed Prostate Cancer After Local Therapy
Enrollment Status: Active_not_recruiting
Publish Date: April 30, 2025
Intervention Type: Drug
Study Drugs: 177Lu-J591, Ketoconazole, Hydrocortisone, 111In-J591
Study Phase: Phase 2
A Phase 2, Open-label, Randomized, Two-stage Clinical Study of Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia Following Treatment With Venetoclax Combination Therapy
A Phase 2, Open-label, Randomized, Two-stage Clinical Study of Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia Following Treatment With Venetoclax Combination Therapy
Enrollment Status: Terminated
Publish Date: November 09, 2023
Intervention Type: Drug
Study Drugs: Alvocidib, Cytarabine
Study Phase: Phase 2
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
Enrollment Status: No_longer_available
Publish Date: July 15, 2020
Intervention Type: Drug
View 7 Less Clinical Trials

16 Total Publications

Partial Response to Small Molecule Inhibition in a Case of Anaplastic Large Cell Lymphoma.
Partial Response to Small Molecule Inhibition in a Case of Anaplastic Large Cell Lymphoma.
Journal: Cureus
Published: March 29, 2022
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Christopher G. Tretter
Hematology Oncology | Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Christopher G. Tretter
Hematology Oncology | Hematology | Oncology

Mainehealth

265 Western Ave, Suite 2, 
South Portland, ME 
 (20.1 miles away)
207-396-7606
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Christopher Tretter is a Hematologist Oncology specialist and a Hematologist in South Portland, Maine. Dr. Tretter is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Renal Cell Carcinoma (RCC), and Chromophobe Renal Cell Carcinoma. Dr. Tretter is currently accepting new patients.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Christian A. Thomas
Hematology Oncology | Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Christian A. Thomas
Hematology Oncology | Hematology | Oncology

Maine Center For Cancer Medicine And Blood Disorders PA

155 Borthwick Ave, Suite C, 
Portsmouth, NH 
 (26.4 miles away)
603-828-0100
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Christian Thomas is a Hematologist Oncology specialist and a Hematologist in Portsmouth, New Hampshire. Dr. Thomas is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Prostate Cancer, Upper Tract Urothelial Carcinoma (UTUC), Familial Prostate Cancer, Lung Cancer, and Nephrectomy.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Meredith J. Selleck
Hematology Oncology | Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Meredith J. Selleck
Hematology Oncology | Hematology | Oncology

New Hampshire Oncology-Hematology PA

250 Pleasant St, 
Concord, NH 
 (52.2 miles away)
603-224-2556
Languages Spoken:
English
See accepted insurances

Meredith Selleck is a Hematologist Oncology specialist and a Hematologist in Concord, New Hampshire. Dr. Selleck is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are B-Cell Lymphoma, Non-Hodgkin Lymphoma, Paget Disease of the Breast, and Lung Cancer.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hajdenberg's expertise for a condition
ConditionClose
      View All 38 Advanced Conditions
      View All 100 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile